BioNTech SE (NASDAQ:BNTX - Free Report) - Research analysts at HC Wainwright upped their Q3 2024 earnings per share estimates for BioNTech in a research note issued on Monday, August 19th. HC Wainwright analyst R. Burns now anticipates that the company will earn $0.85 per share for the quarter, up from their prior estimate of $0.81. HC Wainwright currently has a "Buy" rating and a $113.00 target price on the stock. The consensus estimate for BioNTech's current full-year earnings is ($2.04) per share. HC Wainwright also issued estimates for BioNTech's Q4 2024 earnings at $0.62 EPS, Q3 2025 earnings at $0.82 EPS and Q4 2025 earnings at $0.79 EPS.
Several other equities research analysts have also recently commented on BNTX. BMO Capital Markets dropped their price objective on BioNTech from $123.00 to $122.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 7th. Deutsche Bank Aktiengesellschaft raised BioNTech from a "hold" rating to a "buy" rating and set a $95.00 price objective on the stock in a research report on Wednesday, August 7th. Hsbc Global Res raised BioNTech from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 2nd. TD Cowen dropped their price objective on BioNTech from $98.00 to $85.00 and set a "hold" rating on the stock in a research report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. dropped their price objective on BioNTech from $94.00 to $91.00 and set an "underweight" rating on the stock in a research report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $109.09.
Get Our Latest Report on BioNTech
BioNTech Stock Down 1.6 %
Shares of NASDAQ BNTX traded down $1.40 during trading on Tuesday, reaching $88.53. The company had a trading volume of 642,638 shares, compared to its average volume of 706,164. BioNTech has a 12-month low of $76.53 and a 12-month high of $125.83. The stock has a market cap of $21.05 billion, a PE ratio of 177.06 and a beta of 0.23. The business's 50-day moving average is $84.31 and its 200 day moving average is $89.63. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01.
BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The company had revenue of $128.70 million during the quarter, compared to analysts' expectations of $134.98 million. During the same period in the prior year, the company posted ($0.86) earnings per share. The company's revenue was down 23.3% on a year-over-year basis.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd boosted its position in BioNTech by 2.5% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company's stock worth $492,000 after purchasing an additional 116 shares during the last quarter. Covestor Ltd raised its stake in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company's stock worth $38,000 after buying an additional 133 shares during the period. GAMMA Investing LLC raised its stake in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company's stock worth $25,000 after buying an additional 150 shares during the period. Arlington Capital Management Inc. raised its stake in shares of BioNTech by 10.0% in the first quarter. Arlington Capital Management Inc. now owns 2,200 shares of the company's stock worth $203,000 after buying an additional 200 shares during the period. Finally, Midwest Professional Planners LTD. raised its stake in shares of BioNTech by 7.2% in the first quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company's stock worth $293,000 after buying an additional 212 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Articles
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
